TrialEuropean heart journal2021

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.

Jörg Täubel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.